A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles-Reference-Cited by-同舟云学术

A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles

Published:2014-12-01 Issue:23 Volume:57 Page:9889-9900
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Xia Guangxin¹,Chen Wenteng²,Zhang Jing¹,Shao Jiaan²,Zhang Yong¹,Huang Wei²,Zhang Leduo¹,Qi Weixing²,Sun Xing¹,Li Bojun¹,Xiang Zhixiong¹,Ma Chen¹,Xu Jia¹,Deng Hailin¹,Li Yufeng¹,Li Ping¹,Miao Hong¹,Han Jiansheng¹,Liu Yanjun¹,Shen Jingkang¹³,Yu Yongping²

Affiliation:

1. Central Research Institute, Shanghai Pharmaceutical Holding Co., Ltd., Building 4, No. 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China

2. Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road Zijin Campus, Hangzhou 310058, China

3. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Zhejiang Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm5014659

Reference27 articles.

1. Untangling the ErbB signalling network